Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
NORCROSS, Ga., May 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be attending and presenting at the H.C. Wainwright 2nd Annual BioConnect Investor Conference. Detailed information about the presentation is below.
喬治亞州諾克羅斯，2024年5月13日（GLOBE NEWSWIRE）——靶向半乳糖凝集素蛋白療法的領先開發商Galectin Therapeutics Inc.（納斯達克股票代碼：GALT）今天宣佈，該公司將出席H.C. Wainwright 2並在會上發表演講和 年度生物連接投資者大會。有關該演示文稿的詳細信息如下。
H.C. Wainwright 2nd Annual BioConnect Investor Conference
H.C. Wainwright 2和 年度BioConnect投資者大會
Format: Fireside chat
格式：爐邊聊天
Date and time: May 20, 2024 at 4:00 PM ET
日期和時間：美國東部時間 2024 年 5 月 20 日下午 4:00
Location: Nasdaq World Headquarters, New York City
地點：紐約市納斯達克全球總部
Webcast:
網絡直播：
Galectin management team will be available for one-on-one meetings during the conferences. Interested investors should contact their representative at H.C. Wainwright. A Link to access the webcast will be posted, when available, to the Company's website on the Events & Presentation page of the investors section.
Galectin管理團隊將在會議期間提供一對一的會議。感興趣的投資者應聯繫其在H.C. Wainwright的代表。訪問網絡直播的鏈接將在可用時發佈到公司網站投資者部分的活動和演示頁面上。
About Galectin Therapeutics
關於半乳糖凝集素療法
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at .
Galectin Therapeutics致力於開發新療法，以改善慢性肝病和癌症患者的生活。Galectin的主要藥物belapectin是一種基於碳水化合物的藥物，可抑制半乳糖凝集素-3蛋白，該蛋白直接參與多種炎症、纖維化和惡性疾病，並獲得了美國食品藥品監督管理局的Fast Track認證。主要開發項目是與代謝功能障礙相關的脂肪性肝炎（MASH，前身爲非酒精性脂肪性肝炎，簡稱NASH）和肝硬化，這是最嚴重的MASH相關纖維化。肝硬化是最緊迫的醫療需求之一，也是重要的藥物開發機會。其他開發計劃正在治療晚期頭頸癌和其他惡性腫瘤的聯合免疫療法。這些額外臨床項目的進展在很大程度上取決於尋找合適的合作伙伴。Galectin力求利用廣泛的科學和開發專業知識以及與外部來源的既定關係，實現具有成本效益和高效的開發。其他信息可在以下網址獲得。
Company Contact:
公司聯繫人：
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
傑克·卡利卡特，首席財務官
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contacts:
投資者關係聯繫人：
Kevin Gardner
kgardner@lifesciadvisors.com
凱文·加德納
kgardner@lifesciadvisors.com
Chris Calabrese
ccalabrese@lifesciadvisors.com
克里斯·卡拉布雷斯
ccalabrese@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor GR-MD-02.
Galectin Therapeutics 及其相關徽標是 Galectin Therapeutics Inc. 的註冊商標。Belapectin 是 Galectin Therapeutics 的半乳凝集素-3 抑制劑 GR-MD-02 的美國指定名稱。
譯文內容由第三人軟體翻譯。